We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Vision System Aids Melanoma Detection

By HospiMedica International staff writers
Posted on 17 Nov 2011
A computer-assisted melanoma diagnostic tool helps the detection of atypical cutaneous pigmented lesions.

The MelaFind melanoma diagnostic tool is a point-of-care (POC) multispectral system with a handheld component that captures the image of a lesion with a dermoscope, through a thin layer of alcohol applied to the skin. More...
Multiple light wavelengths are used to obtain data from images of suspicious pigmented skin lesions; the data are then analyzed against a proprietary database of melanomas and benign lesions stored on a central computer, using sophisticated algorithms. A report is then transmitted to the physician’s office containing a recommendation of whether the lesion should be biopsied.

The MelaFind is designed to be used only when a dermatologist chooses to obtain additional information for a decision to biopsy, and not to confirm a clinical diagnosis of melanoma. It is not intended to be used as a screening tool or in the evaluation of nonpigmented lesions; banal pigmented lesions; lesions considered definite melanomas; or mucosal, subungual, and other lesions at different anatomic sites. The MelaFind was developed by MELA Sciences (Irvington, NY, USA), and has been approved by the US Food and Drug Administration (FDA).

“There is no such thing as 100% certainty in medicine,” said George Elias, MD, a melanoma expert at Georgetown University (Washington DC, USA). “Ultimately it's the responsibility of the dermatologist to use his clinical judgment to make the best decision. This machine is there to help him, not replace him.”

The device was used by dermatologists in a pivotal study of 1,257 patients (mean age 47 years) on 1,632 pigmented skin lesions that had at least one characteristic of melanoma, which were also biopsied. Of the 114 lesions that were positive for melanoma on biopsy, 112 were tagged as positive by MelaFind, representing a sensitivity of 98.3%, compared to a sensitivity of 70% to 80% for dermatologists reported in the literature.

Melanoma is a malignant tumor of melanocytes. They predominantly occur in skin, but are also found in other parts of the body, including the bowel and the eye. Melanoma is less common than other skin cancers, but it is much more dangerous and causes the majority (75%) of deaths related to skin cancer. Treatment includes surgical removal of the tumor, adjuvant treatment, chemotherapy and immunotherapy, or radiation therapy. The chance of a cure is greatest when the tumor is discovered while it is still small and thin, and can be entirely removed surgically.

Related Links:

MELA Sciences
Georgetown University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Digital Radiography System (Ceiling Free)
Digix CF Series
New
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.